Rate Video

ASCO 2020 | Horizon scanning in lung cancer

Sanjay Popat • 11 Jun 2020

Lung Cancer Non-Small Cell Lung Cancer

Immuno-Oncology

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, gives his perspective on where immunotherapy for patients with lung cancer will be heading in the next couple of years. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Update from a phase 1 study of AMG 757 in SCLC

Sanjay Popat • 31 Mar 2021

ASCO preview: SCLC

Sanjay Popat • 15 May 2020

NICE approval of brigatinib in ALK-positive NSCLC

Sanjay Popat • 31 Mar 2021

ETOP/IFCT 4-12 STIMULI updates from ESMO 2020

Sanjay Popat • 2 Oct 2020

Related Videos

Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer

Heather A. Wakelee • 9 Jun 2021

IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC

Heather A. Wakelee • 9 Jun 2021

Bispecific antibodies in lung cancer

Benjamin Besse • 7 Jun 2021

The future of NSCLC treatment

Benjamin Besse • 7 Jun 2021